Skip to main content

Table 1 Clinic-pathological characteristics of p-Met and DR5 coexpression in PTC.a

From: c-Met Inhibitor Synergizes with Tumor Necrosis Factor-Related Apoptosis-Induced Ligand to Induce Papillary Thyroid Carcinoma Cell Death

 

Total

Both high

Both low

 
 

No.

 

No.

%

No.

%

P

No. of patients

196

 

85

43.4

111

56.6

 

Age, years

≤45

102

52.0

32

31.4

70

68.6

0.0004

>45

94

48.0

53

56.4

41

43.6

 

Extrathyroidal extension

Absent

87

44.4

32

36.8

55

63.2

0.0956

Present

109

55.6

53

48.6

56

51.4

 

Stagea

I

100

54.3

35

35.0

65

65.0

0.0146

II

11

6.0

3

27.3

8

72.7

 

III

19

10.3

13

68.4

6

31.6

 

IV

54

29.4

28

51.8

26

48.2

 

p-AKTb

High (2–3)

91

50.0

51

56.0

40

44.0

0.0045

Low (0–1)

91

50.0

32

35.2

59

64.8

 

PIK3CA-IHCb

High

139

71.7

73

52.5

66

47.5

<0.0001

Low

55

28.3

12

21.8

43

78.2

 

BCLXLb

High

50

25.6

30

60.0

20

40.0

0.0068

Low

145

74.4

55

37.9

90

62.1

 

XIAPb

High

70

36.1

40

57.1

30

42.9

0.0049

Low

124

63.9

45

36.3

79

63.7

 

HGF-1b

High

38

21.0

30

79.0

8

21.0

<0.0001

Low

143

79.0

49

34.3

94

65.7

 

c5-Year disease-free survival

   

75.6

 

65.2

0.9623

  1. aStage information was not available in 12 of the 196 PTC cases with data available for coexpression of p-Met and DR5.
  2. bIHC was noninformative in some TMA spots ranging from 1 to 15 indicated in parenthesis: p-AKT (14); PIK3CA, PTEN and XIAP (2 each); BCL-XL (1); HGF-1 (15).
  3. cDisease-free survival data were available for some patients but the remaining patients for whom disease-free survival data were not available were excluded from survival analysis.